Biocon’s accomplice Equillium plans Itolizumab’s worldwide clinical preliminary for COVID-19 Kumar Jeetendra | July 13, 2020 Biocon’s partner Equillium has said it is planning to conduct a global randomised controlled clinical trial of Itolizumab in COVID-19 patients, for the American biotech firm will record a US investigational new drug application (IND). Itolizumab, which is used for the treatment of psoriasis, is repurposed for COVID-19, as it regulates the production of inflammatory …
Minitsry of Health rules against incorporating Itolizumab in clinical administration convention for COVID-19 Kumar Jeetendra | July 26, 2020 The National Task Force on COVID-19 has ruled against incorporating Itolizumab medicate in clinical administration conventions for rewarding the malady despite the fact that the DCGI has affirmed its “confined crisis use” in contaminated patients, official sources said. Considering the neglected clinical needs in COVID-19, Itolizumab, a previously endorsed medication of Biocon, utilized for rewarding …
